UNSPSC 51473101: Fludazonium

This classification denotes an anti-infective agent with the molecular formula C26H20Cl4FN2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier K23V2Z5820, chemically known as 1h-imidazolium, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl)methoxy)ethyl)-3-(2-(4-fluorophenyl)-2-oxoethyl)- but generally known as fludazonium, which bears US NIH Compound Identifier 216229. European Medicines Agency schedules Fludazonium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07679MIG.

UNSPSC 51473101 Fludazonium, a Commodity code, captures consumable chemical or pharmaceutical products that state and local governments procure for operational and clinical use across fire rescue, healthcare, and other public facilities. State and local issuers soliciting under this code include county boards of commissioners, state health and human services departments, and multi-state cooperative purchasing alliances. The work ranges from as-needed supply replenishment for fire rescue operations to bulk pharmaceutical procurement through established wholesaler networks, with vendors required to hold manufacturer credentials, maintain authorized distributor status, and provide chain-of-custody documentation and rapid delivery or fulfillment.

Recent activity shows geographic spread across the upper Midwest and Southeast. Hillsborough County Board of County Commissioners in Florida posted ITB2600319 on July 7, 2026 (due July 24, 2026) for consumable janitorial and operational supplies for the Hillsborough County Fire Rescue Department, with an estimated contract value of $765,679.84 for one year; the County reserves the right to award by line item or overall net bid and shares contracts with the Hillsborough County Governmental Purchasing Council. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 on January 20, 2026 (due March 26, 2026) for generic multi-source pharmaceuticals and over-the-counter products, requiring manufacturers to submit detailed NDC, SKU, and UPC specifications with pricing effective July 1, 2026, and evaluation weighted 75 percent on price competitiveness, 10 percent on fixed pricing, and the remainder on EDI capability, compliance with administrative fee formats, and manufacturing-practice certification.